Trinity Biotech has announced plans to enter the expanding continuous glucose monitor (CGM) market with its upcoming next-generation wearable biosensor, CGM+.
As reported by Drug Delivery Business News, the Dublin-based company is in the advanced stages of developing CGM+, a modular, AI-native biosensor designed to meet the growing demand for intelligent wearables in both healthcare and wellness applications.
Unlike conventional CGM systems that focus exclusively on glucose levels, CGM+ integrates multiple physiological measurements into a single, sleek wearable. The device pairs a minimally invasive electrochemical glucose sensor with real-time monitoring of heart activity, body temperature, and physical activity—enabling a more comprehensive picture of the user's health.
Trinity Biotech says CGM+ will leverage AI-driven analytics to interpret data from these sensors, delivering actionable insights and enhancing proactive health management. The system’s modular design and user-friendly interface aim to improve adoption across both clinical and consumer wellness markets.
With this announcement, Trinity Biotech joins the race to develop advanced biosensors that go beyond glucose, tapping into the rapidly evolving AI-powered wearables space.